Skip to main content

Table 1 Baseline patient demographics in the mistletoe and non-mistletoe groups

From: Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

Variables

MG (n = 15)

NMG (n = 37)

P-value

Age (years)

68 (38–83)

67 (46–86)

0.864

Sex

  

0.525

 Male

9 (60.0)

26 (70.3)

 

 Female

6 (40.0)

11 (29.7)

 

BMI (kg/m2)

23.4 (20.8–28.3)

24.4 (15.1–31.5)

0.473

ASA score

  

0.254

 1

0

4 (10.8)

 

 2

15 (100)

30 (81.1)

 

 Unknown

0

3 (8.1)

 

Past history

   

 Diabetes

5 (33.3)

8 (21.6)

0.483

 Cardiovascular disease

7 (46.7)

18 (48.6)

0.897

 Others

5 (33.3)

13 (35.1)

0.902

Baseline tumor markers

   

 CEA (ng/mL)

2.9 (0.5–43.7)

2.9 (0.6–44.9)

0.992

 CA 19-9 (U/mL)

4.2 (1.2–184.7)

12.1 (1.2–1222.8)

0.010†,**

Tumor distance from the AV (cm)

3.6 (0–10.0)

6.0 (2.0–10.0)

0.008†,**

MRF involvement

  

0.314

 Yes

10 (66.7)

19 (51.4)

 

 No

5 (33.3)

18 (48.6)

 

cT before NCRT

  

0.412

 cT2

1 (6.7)

0

 

 cT3

12 (80.0)

32 (86.5)

 

 cT4

2 (13.3)

5 (13.5)

 

cN before NCRT

  

0.086

 cN0

0

3 (8.1)

 

 cN1

7 (46.7)

6 (16.2)

 

 cN2

8 (53.3)

28 (75.7)

 

Baseline clinical stage (AJCC 8th edition)

  

0.548

 Stage II

0

3 (8.1)

 

 Stage III

15 (100)

34 (91.9)

 
  1. Data are presented as median (range) for continuous variables and n (%) for categorical variables
  2. Mann–Whitney test; chi-square test or Fisher’s exact test; **statistical significance (P < 0.05)
  3. MG, mistletoe group; NMG, non-mistletoe group; BMI, body mass index; ASA, American Society of Anesthesiologist; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; AV, anal verge; MRF, mesorectal fascia; NCRT, neoadjuvant chemoradiotherapy; AJCC, American Joint Committee on Cancer